Barclays Initiates Natera(NTRA.US) With Buy Rating, Announces Target Price $200
Natera Initiated With an Overweight at Barclays
BTIG Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $185
Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and Natera (NTRA)
Natera Analyst Ratings
Guggenheim Maintains Natera(NTRA.US) With Buy Rating, Announces Target Price $200
Bernstein Keeps Their Buy Rating on Natera (NTRA)
Natera's Strong Market Position and Growth Potential Drive Buy Rating
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $210
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $195
TD Cowen Remains a Buy on Natera (NTRA)
Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $200
Positive Outlook for Natera: Buy Rating Driven by Strong Revenue Performance and Strategic Developments
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $174
Craig-Hallum Sticks to Their Buy Rating for Natera (NTRA)
Natera Is Maintained at Buy by Canaccord Genuity
Natera Analyst Ratings
CCORF Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $180
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $195